IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v31y2013i4p257-267.html
   My bibliography  Save this article

Korean Guidelines for Pharmacoeconomic Evaluation (Second and Updated Version)

Author

Listed:
  • SeungJin Bae
  • SooOk Lee
  • Eun Bae
  • Sunmee Jang

Abstract

The first version of the Korean guidelines for pharmacoeconomic evaluation was published by Health Insurance Review and Assessment Service (HIRA) in 2006. Since the introduction of the first version, domestic experience with the application of the recommendations has accumulated, and methodologies in certain areas have progressed considerably. Based on these experiences, HIRA initiated a guidelines revision project to address the need for revisions. The purpose of this study is to share the process used to complete these guideline revisions and to provide the contents of the revised guidelines. In developing the current revision, meetings with the advisory committee and working-level meetings with pharmaceutical companies were held several times to reach as much of a consensus as possible, and the results of a survey of pharmaceutical companies and decision makers regarding the existing guidelines were considered. The second version of the guidelines clarified the level of data requirement (‘must’, ‘recommended’, ‘preferred’) based on the data availability, the information needs of the decision makers and the strength of the evidence. The recommended perspective economic studies should take has been modified and additional guidance has been provided on QALY measurement. Manuals for systematic reviews and indirect comparisons have been published, and a standardized reporting format for expert opinions has been added. Sections on preferred methods for evaluations, sensitivity analysis, modelling and time horizon have been elucidated. The revised guidelines clarify the expression of the recommendations, making them more user-friendly, and provide more specific guidance to improve the quality and comparability across submissions. Copyright Springer International Publishing Switzerland 2013

Suggested Citation

  • SeungJin Bae & SooOk Lee & Eun Bae & Sunmee Jang, 2013. "Korean Guidelines for Pharmacoeconomic Evaluation (Second and Updated Version)," PharmacoEconomics, Springer, vol. 31(4), pages 257-267, April.
    • Handle: RePEc:spr:pharme:v:31:y:2013:i:4:p:257-267
    DOI: 10.1007/s40273-012-0021-6
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40273-012-0021-6
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s40273-012-0021-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. John Brazier & Jennifer Roberts & Aki Tsuchiya & Jan Busschbach, 2004. "A comparison of the EQ‐5D and SF‐6D across seven patient groups," Health Economics, John Wiley & Sons, Ltd., vol. 13(9), pages 873-884, September.
    2. Julio López-Bastida & Juan Oliva & Fernando Antoñanzas & Anna García-Altés & Ramón Gisbert & Javier Mar & Jaume Puig-Junoy, 2010. "Spanish recommendations on economic evaluation of health technologies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(5), pages 513-520, October.
    3. Garber, Alan M. & Phelps, Charles E., 2008. "Future costs and the future of cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 27(4), pages 819-821, July.
    4. Richard Norman & Paula Cronin & Rosalie Viney & Madeleine King & Deborah Street & John Brazier & Julie Ratcliffe, 2007. "Valuing EQ-5D health states: A review and analysis, CHERE Working Paper 2007/9," Working Papers 2007/9, CHERE, University of Technology, Sydney.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Green Bae & SeungJin Bae & Donghwan Lee & Juhee Han & Dong-Hoe Koo & Do Yeun Kim & Hee-Jun Kim & Sung Young Oh & Hee Yeon Lee & Jong Hwan Lee & Hye Sook Han & Hyerim Ha & Jin Hyoung Kang, 2021. "Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology," IJERPH, MDPI, vol. 18(6), pages 1-10, March.
    2. Bae, Green & Bae, Eun Young & Bae, SeungJin, 2015. "Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea," Health Policy, Elsevier, vol. 119(5), pages 577-587.
    3. Bae, Eun-Young & Hong, Ji-Min & Kwon, Hye-Young & Jang, Suhyun & Lee, Hye-Jae & Bae, SeungJin & Yang, Bong-Min, 2016. "Eight-year experience of using HTA in drug reimbursement: South Korea," Health Policy, Elsevier, vol. 120(6), pages 612-620.
    4. Gyeyoung Choi & Yujeong Kim & Gyeongseon Shin & SeungJin Bae, 2022. "Projecting Lifetime Health Outcomes and Costs Associated with the Ambient Fine Particulate Matter Exposure among Adult Women in Korea," IJERPH, MDPI, vol. 19(5), pages 1-14, February.
    5. Jeewon Park & SeungJin Bae, 2020. "Modeling Healthcare Costs Attributable to Secondhand Smoke Exposure at Home among South Korean Children," IJERPH, MDPI, vol. 17(12), pages 1-12, June.
    6. Jiryoun Gong & Juhee Han & Donghwan Lee & Seungjin Bae, 2020. "A Meta-Regression Analysis of Utility Weights for Breast Cancer: The Power of Patients’ Experience," IJERPH, MDPI, vol. 17(24), pages 1-16, December.
    7. Matthew Kennedy-Martin & Bernhard Slaap & Michael Herdman & Mandy Reenen & Tessa Kennedy-Martin & Wolfgang Greiner & Jan Busschbach & Kristina S. Boye, 2020. "Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(8), pages 1245-1257, November.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Brazier, JE & Yang, Y & Tsuchiya, A, 2008. "A review of studies mapping (or cross walking) from non-preference based measures of health to generic preference-based measures," MPRA Paper 29808, University Library of Munich, Germany.
    2. Joel Thompson & Amir Abdolahi & Katia Noyes, 2013. "Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis," PharmacoEconomics, Springer, vol. 31(6), pages 455-469, June.
    3. Hirsch Ruchlin & Ralph Insinga, 2008. "A Review of Health-Utility Data for Osteoarthritis," PharmacoEconomics, Springer, vol. 26(11), pages 925-935, November.
    4. Tsuchiya, Aki & Brazier, John & Roberts, Jennifer, 2006. "Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets," Journal of Health Economics, Elsevier, vol. 25(2), pages 334-346, March.
    5. Antonio García-Ruiz & Lucía Pérez-Costillas & Ana Montesinos & Javier Alcalde & Itziar Oyagüez & Miguel Casado, 2012. "Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses," Health Economics Review, Springer, vol. 2(1), pages 1-12, December.
    6. Ayse Kuspinar & Nancy Mayo, 2014. "A Review of the Psychometric Properties of Generic Utility Measures in Multiple Sclerosis," PharmacoEconomics, Springer, vol. 32(8), pages 759-773, August.
    7. Marco DiBonaventura & Lance Richard & Maya Kumar & Anna Forsythe & Natalia M Flores & Margaret Moline, 2015. "The Association between Insomnia and Insomnia Treatment Side Effects on Health Status, Work Productivity, and Healthcare Resource Use," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-14, October.
    8. J Lennert Veerman & Jan J Barendregt & Megan Forster & Theo Vos, 2011. "Cost-Effectiveness of Pharmacotherapy to Reduce Obesity," PLOS ONE, Public Library of Science, vol. 6(10), pages 1-8, October.
    9. Efthymiadou, Olina & Mossman, Jean & Kanavos, Panos, 2019. "Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients," Health Policy, Elsevier, vol. 123(2), pages 159-165.
    10. C. Rubio-Terrés & J. Soria & P. Morange & J. Souto & P. Suchon & J. Mateo & N. Saut & D. Rubio-Rodríguez & J. Sala & A. Gracia & S. Pich & E. Salas, 2015. "Economic Analysis of Thrombo inCode, a Clinical–Genetic Function for Assessing the Risk of Venous Thromboembolism," Applied Health Economics and Health Policy, Springer, vol. 13(2), pages 233-242, April.
    11. Marieke Krol & Elly Stolk & Werner Brouwer, 2014. "Predicting productivity based on EQ-5D: an explorative study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(5), pages 465-475, June.
    12. M. Barbieri & H. Weatherly & R. Ara & H. Basarir & M. Sculpher & R. Adams & H. Ahmed & C. Coles & T. Guerrero-Urbano & C. Nutting & M. Powell, 2014. "What is the Quality of Economic Evaluations of Non-Drug Therapies? A Systematic Review and Critical Appraisal of Economic Evaluations of Radiotherapy for Cancer," Applied Health Economics and Health Policy, Springer, vol. 12(5), pages 497-510, October.
    13. Rivero-Santana, Amado & Cuéllar-Pompa, Leticia & Sánchez-Gómez, Luis M. & Perestelo-Pérez, Lilisbeth & Serrano-Aguilar, Pedro, 2014. "Effectiveness and cost-effectiveness of different immunization strategies against whooping cough to reduce child morbidity and mortality," Health Policy, Elsevier, vol. 115(1), pages 82-91.
    14. Laura Amanda Vallejo-Aparicio & Jesús Molina & Iñigo Ojanguren & Ana Viejo Casas & Alicia Huerta & Henrik Svedsater, 2020. "Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(1), pages 7-17, February.
    15. Rowen, D & Brazier, J & Tsuchiya, A & Hernández, M & Ibbotson, R, 2009. "The simultaneous valuation of states from multiple instruments using ranking and VAS data: methods and preliminary results," MPRA Paper 29841, University Library of Munich, Germany.
    16. Matthew Franklin & Clara Mukuria & Brendan Mulhern & Irwin Tran & John Brazier & Stuart Watson, 2019. "Measuring the Burden of Schizophrenia Using Clinician and Patient-Reported Measures: An Exploratory Analysis of Construct Validity," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 12(4), pages 405-417, August.
    17. Santiago Grau & Rafael Cámara & Manuel Jurado & Jaime Sanz & Belén Aragón & Irmina Gozalbo, 2018. "Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplant," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 627-636, May.
    18. David Feeny, 2012. "The Multi-attribute Utility Approach to Assessing Health-related Quality of Life," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 36, Edward Elgar Publishing.
    19. D. Stratmann‐Schoene & T. Kuehn & R. Kreienberg & R. Leidl, 2006. "A preference‐based index for the SF‐12," Health Economics, John Wiley & Sons, Ltd., vol. 15(6), pages 553-564, June.
    20. Stavros Petrou & Christine Hockley, 2005. "An investigation into the empirical validity of the EQ‐5D and SF‐6D based on hypothetical preferences in a general population," Health Economics, John Wiley & Sons, Ltd., vol. 14(11), pages 1169-1189, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:31:y:2013:i:4:p:257-267. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.